Insights On Upstream Manufacturing

  1. 4 Steps To Process Intensification Success In Biomanufacturing 3/4/2026

    For successful process intensification (PI) adoption, consider the key steps to success, including how to commit to a long-term strategy, navigate scale-up challenges, and identify ideal use cases.

  2. Activate Process Intensification Strategies To Increase Productivity 3/4/2026

    Amid pressure to cut costs, improve sustainability, and compete with biosimilars, process intensification has emerged as a compelling option to increase yields and future-proof operations.

  3. Mesenchymal Stromal Cells: The Progress And Manufacturing Challenges 2/27/2026

    Understand the manufacturing challenges where rapid cell expansion often conflicts with therapeutic secretion profiles, requiring sophisticated quality control and donor selection strategies.

  4. Getting Your Proof Of Clonality Right For Regulators 2/27/2026

    Regulators require clear, verifiable proof that production cell lines originate from a single progenitor cell, supported by strong imaging, documentation, and data integrity to ensure product consistency and safety.

  5. What Makes A Cell Bank 'GMP-Ready'? 2/27/2026

    A GMP‑ready cell bank requires controlled stability, sterility, genetic integrity, and complete documentation to ensure consistent, safe biologic production and meet regulatory expectations.

  6. CHO Cell Line Performance With 2G UNic® Technology 2/27/2026

    Optimized vector designs significantly enhance CHO cell protein expression, yielding higher titers, better stability, and strong performance across diverse host lines and scale‑up stages.

  7. How Early Data Drives Better Cell Line Performance 2/27/2026

    Structured early data strengthens clonality assurance, stability, and tech transfer, supporting consistent performance, lower variability, and smoother progression to manufacturing.

  8. A Journey To Produce MSC-Derived Cell Therapies From Isolation To Large-Scale 2/26/2026

    Drive successful MSC therapy development by optimizing isolation methods, surface chemistry, and closed-system expansion technologies to ensure cellular stability and commercial scalability.

  9. Scaling MSC Therapies: Overcoming Cell Therapy Manufacturing Risks And Barriers 2/26/2026

    Achieve scalable MSC manufacturing by implementing closed systems and modular scale-out strategies that minimize contamination risks and ensure consistent cellular stability and efficacy.

  10. Laboratory Cell Line Development 2/24/2026

    Efficient cell line development demands reliable clone selection and early removal of candidates. Filtration and sample prep solutions can strengthen sterility, simplify workflows, and support decisions.